References
- Apple F. S., Jesse R. L., Newby L. K., Wu A. H., Christenson R. H. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes. Circulation 2007; 115: e352–55
- Venge P., Johnston N., Lagerqvist B., Wallentin L., Lindahl B. Clinical and analytical performance of the liaison cardiac troponin I assay in unstable coronary artery disease, and the impact of age on the definition of reference limits. A FRISC‐II substudy. Clin Chem 2003; 49: 880–6
- Zethelius B., Johnston N., Venge P. Troponin I as a predictor of coronary heart disease and mortality in 70‐year‐old men: a community‐based cohort study. Circulation 2006; 113: 1071–8
- Apple F. S., Quist H. E., Doyle P. J., Otto A. P., Murakami M. M. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem 2003; 49: 1331–6
- Hedstrand H. A study of middle‐aged men with particular reference to risk factors for cardiovascular disease. Ups J Med Sci Suppl 1975; 19: 1–61
- Byberg L., McKeigue P. M., Zethelius B., Lithell H. O. Birth weight and the insulin resistance syndrome: association of low birth weight with truncal obesity and raised plasminogen activator inhibitor‐1 but not with abdominal obesity or plasma lipid disturbances. Diabetologia 2000; 43: 54–60
- Uettwiller‐Geiger D., Wu A. H., Apple F. S., Jevans A. W., Venge P., Olson M. D., Darte C., Woodrum D. L., Roberts S., Chan S. Multicenter evaluation of an automated assay for troponin I. Clin Chem 2002; 48: 869–76
- Venge P., Lindahl B., Wallentin L. New generation cardiac troponin I assay for the access immunoassay system. Clin Chem 2001; 47: 959–61
- Eggers K. M., Lagerqvist B., Venge P., Wallentin L., Lindahl B. Persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome predicts long‐term mortality. Circulation 2007; 116: 1907–14
- Zethelius B., Berglund L., Sundstrom J., Ingelsson E., Basu S., Larsson A., Venge P., Arnlov J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107–16
- Braunwald E. Changing the practice of cardiovascular medicine. Atheroscler Suppl 2001; 2: 27–30
- Poirier P., Eckel R. H. Obesity and cardiovascular disease. Curr Atheroscler Rep 2002; 4: 448–53
- Topol E. J. A guide to therapeutic decision‐making in patients with non‐ST‐segment elevation acute coronary syndromes. J Am Coll Cardiol 2003; 41(4 Suppl S): S123–9
- Heeschen C. Biomarkers in acute coronary syndromes and their role in diabetic patients. Diab Vasc Dis Res 2005; 2: 122–7
- James S. K., Lindback J., Tilly J., Siegbahn A., Venge P., Armstrong P., Califf R., Simoons M. L., Wallentin L., Lindahl B. Troponin‐T and N‐terminal pro‐B‐type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO‐IV substudy. J Am Coll Cardiol 2006; 48: 1146–54
- Jernberg T., James S., Lindahl B., Stridsberg M., Venge P., Wallentin L. NT‐proBNP in unstable coronary artery disease – experiences from the FAST, GUSTO IV and FRISC II trials. Eur J Heart Fail 2004; 6: 319–25
- Chatha K., Alsoud M., Griffiths M. J., Elfatih A., Abozguia K., Horton R. C., Dunmore S. J., Gama R. B‐type natriuretic peptide in reversible myocardial ischaemia. J Clin Pathol 2006; 59: 1216–17
- Wagner J. A., Stork S., Weidemann F., Strotmann J., Fiedel C., Ertl G., Voelker W. Natriuretic peptides and myocardial oxygen supply‐to‐demand ratio in patients with aortic stenosis. Eur J Clin Invest 2007; 37: 463–71
- Riezebos R. K., Ronner E., Tijssen J. G., Laarman G. J. NT‐ProBNP serum levels reflect severity and extent of ischemia in patients admitted with non‐ST‐elevation acute coronary syndrome. Acute Card Care 2006; 8: 51–7
- Goetze J. P., Gore A., Moller C. H., Steinbruchel D. A., Rehfeld J. F., Nielsen L. B. Acute myocardial hypoxia increases BNP gene expression. FASEB J 2004; 18: 1928–30
- Omland T., Sabatine M. S., Jablonski K. A., Rice M. M., Hsia J., Wergeland R., Landaas S., Rouleau J. L., Domanski M. J., Hall C., Pfeffer M. A., Braunwald E. Prognostic value of B‐Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol 2007; 50: 205–14